NIH Peer Review Changes for 2027: What “Competitive but Not Discussed” Means for Your Grant
Receiving an NIH summary statement marked “competitive but not discussed” can be confusing. It does not mean that the application was overlooked, rejected, or removed from funding consideration.
Under NIH’s temporary modified peer-review process, applications placed in the middle third by the review committee receive the “competitive but not discussed” designation. These applications are not discussed or given an overall impact score, but they can still be considered for funding.
The designation is important—but it is not a funding decision. Applicants should evaluate the written critiques, speak with the appropriate NIH program official, and make a deliberate decision about whether to wait, revise, or resubmit.
Current-policy note: NIH has announced that these modified review practices will remain in effect through the January 2027 Advisory Council round. Applicants should confirm the latest NIH guidance for later review cycles.
Why did NIH change peer review?
NIH introduced temporary modifications after a lapse in appropriations created a backlog of peer-review meetings. To process that application volume while maintaining review operations, NIH reduced the share of applications discussed at most meetings from approximately 50% to about 30%–35%.
Applications are separated into three general groups:
· Top group: Approximately 30%–35% are discussed by the review committee and remain eligible for funding.
· Middle group: These applications are designated “competitive but not discussed” and also remain eligible for funding.
· Lowest group: These applications are designated “not competitive and not discussed.”
A strong application can therefore receive the middle designation simply because fewer applications are being discussed—not necessarily because reviewers considered the underlying project unworthy of support.
What does “competitive but not discussed” mean?
A “competitive but not discussed” application has been judged to possess scientific and technical merit but was not selected for discussion during the study-section meeting. It receives no overall impact score and no résumé of the committee’s discussion.
The summary statement should still include the written critiques from the three assigned reviewers. NIH identifies the designation near the top of the first page of the summary statement.
Most importantly, the application may still be considered for funding. NIH program staff can recommend an application to the relevant Institute or Center director based on factors such as programmatic priority, portfolio balance, mission alignment, and available funds.
That does not mean funding is likely or guaranteed. It means that “not discussed” should not automatically be interpreted as “rejected.”
NIH is also using a shorter summary format during the modified process. Discussed applications receive a sentence describing the degree of consensus and bullets identifying the principal score-driving points rather than the former narrative summary of the committee discussion.
What should applicants do next?
Read all three critiques together
Do not focus only on the harshest sentence or a single reviewer’s opinion. Identify concerns that appear across multiple critiques, then separate them into four categories:
· Importance and potential impact of the research
· Rigor and feasibility of the approach
· Expertise and resources
· Administrative or application-specific concerns
This structure reflects NIH’s simplified review framework for most research project grants. Under that framework, reviewers consider the importance of the research, the rigor and feasibility of the work, and whether the required expertise and resources are in place.
Distinguish isolated concerns from recurring concerns
A comment raised by one reviewer may require clarification. A concern repeated by two or three reviewers is more likely to indicate a fundamental weakness in the proposal’s logic, evidence, feasibility, team, or presentation.
Create a critique matrix with one row for each concern and columns for:
· Which reviewers raised it
· Whether it affects significance, feasibility, or execution
· What new evidence or explanation would resolve it
· Which application section must change
· Whether the change can be completed before the next relevant deadline
This prevents a resubmission from becoming a collection of disconnected edits.
Contact the program official
NIH encourages applicants to consider discussing the summary statement with the appropriate program staff. Useful questions include:
· How does the project align with the Institute or Center’s current priorities?
· Is the application realistically positioned for further funding consideration?
· Would a resubmission be advisable?
· Are there particular reviewer concerns that should be prioritized?
· Is the same funding opportunity still the best fit?
The conversation should focus on interpretation and strategic direction. A program official cannot rewrite the proposal, guarantee an award, or eliminate the need to respond carefully to the critiques.
Do not wait passively
Because a competitive-but-not-discussed application remains eligible for funding, it may be tempting to postpone all revision work. That can create unnecessary deadline pressure if the ultimate funding decision is unfavorable.
A stronger approach is to begin evaluating the critiques while awaiting further guidance. Teams can identify missing preliminary evidence, reconsider milestones, confirm collaborator availability, and determine whether a revised research strategy would materially strengthen the next submission.
Decide whether revision is enough
Not every critique can be solved by adding a paragraph. Some applications need a more substantial change, such as:
· Stronger preliminary data
· A narrower or more feasible scope
· Better-defined milestones and go/no-go criteria
· Additional technical or clinical expertise
· A clearer connection between the unmet need and the proposed research
· Better alignment between the research plan and commercialization strategy for an SBIR or STTR application
The goal is not merely to answer every comment. The goal is to submit a more persuasive and fundable application.
What should future applicants learn from this?
The modified process increases the importance of making the application’s central case easy to understand before the study-section meeting begins. The assigned reviewers’ written evaluations carry particular importance when fewer applications receive full committee discussion.
For most research project grants covered by NIH’s simplified framework, reviewers organize their analysis around three practical questions:
1. Should the research be done? This addresses the project’s importance, significance, and relevant innovation.
2. Can the research be done well? This addresses rigor, feasibility, methods, and the likelihood of producing robust findings.
3. Are the expertise and resources in place? This addresses the team and research environment.
A technically complete application can still struggle if reviewers must work too hard to find the answers. Clear Specific Aims, a defensible approach, credible milestones, and an appropriately assembled team should reinforce one coherent funding case.
How Blue Haven can help
A summary statement is more than a list of edits. It provides evidence about how reviewers understood the project, which arguments persuaded them, and where confidence weakened.
Blue Haven Grant Consultants helps applicants evaluate reviewer feedback, identify the highest-priority weaknesses, and determine whether the strongest next step is a targeted revision, a more substantial repositioning, or a different NIH funding strategy.
For new applications, the team helps researchers and small businesses build a reviewer-centered narrative that connects the importance of the work, the rigor and feasibility of the research plan, and the qualifications of the team.
Received an NIH summary statement and unsure what to do next?
Schedule a confidential NIH application consultation to discuss the critiques, funding fit, and potential resubmission strategy.
This article is for informational purposes and does not guarantee that an application will be funded. NIH policies and review practices may change; applicants should consult the applicable funding opportunity and current NIH guidance.